Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Recommendation of “Hold” by Brokerages

Gyre Therapeutics, Inc. (NASDAQ:GYRE) has received an average rating of “Hold” from the five brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $17.00.

A number of research firms have issued reports on GYRE. Zacks Research upgraded shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Gyre Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 15th.

Gyre Therapeutics Price Performance

Shares of Gyre Therapeutics stock opened at $8.28 on Monday. The firm has a market cap of $797.61 million, a price-to-earnings ratio of 276.09 and a beta of 1.97. The stock has a 50-day simple moving average of $7.68 and a 200-day simple moving average of $7.74. Gyre Therapeutics has a 52-week low of $6.11 and a 52-week high of $13.75.

Institutional Investors Weigh In On Gyre Therapeutics

Large investors have recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue acquired a new stake in shares of Gyre Therapeutics in the third quarter worth $38,000. Bank of America Corp DE raised its holdings in Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after acquiring an additional 1,402 shares during the period. JPMorgan Chase & Co. lifted its position in Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after acquiring an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Gyre Therapeutics by 77.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after acquiring an additional 3,244 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in Gyre Therapeutics during the fourth quarter valued at about $77,000. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.